BioSpace News Archive

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Kathleen W. Tregoning as chief corporate affairs officer.

“With the new strategy announced in early April, we have put a stronger focus on Alligator’s clinical development portfolio.

The study published in Clinical Ophthalmology shows equivalent clinical outcomes to separately dosed eyedrops and a strong patient preference for the ImprimisRx proprietary combination drop therapy for postoperative care

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, provided an overview and update of clinical and pre-clinical programs currently being researched and develo

Global biopharmaceutical company Bristol Myers Squibb, based in Princeton , NJ, has earned the prestigious global CEO Cancer Gold Standard ™ accreditation for its ongoing commitment to reduce cancer risk for employees and their family members around the world.

– Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS) Will Make Lumasiran Treatment Available for UK Primary Hyperoxaluria Type 1 (PH1) Patients Before Marketing Authorization -- – Lumasiran Indicated Within EAMS for the Treatment of Patients with PH1 --

Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels Data confirm Phase 3 study design to treat acute bleeding events in hemophilia

Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products for large unmet needs in procedure-based medicine, today announced the appointment of Jagdish Parasrampuria M.Pharm., Ph.D., as Vice President of Pharmaceutical Development. Dr. Parasrampuria is an expert in small molecules, biologics, and drug-device combination products and will play a leadersh

Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for patients switching from twice-nightly sodium oxybate to once-nightly FT218

The McGuire Institute Study Compared Traditional Treatments for Periodontitis to BIOLASE REPAIR Perio Protocol